University of Auckland - DIGIPREDICT

Exhibitor

DIGIPREDICT is a University of Auckland spin-out developing a Software as a Medical Device (SaMD) designed to predict asthma attacks before they happen – giving patients and their clinicians time to act, days before an attack occurs.

Current asthma management is reactive. Patients wait for symptoms. DIGIPREDICT changes this by continuously and passively analysing physiological signals from a consumer smartwatch to detect the early pre-symptomatic digital signature of deteriorating asthma. No new hardware. No active monitoring. Just intelligent, personalised early warnings.

Our algorithm has demonstrated high accuracy in an observational study of 200+ patients using smartwatch data alone – outperforming symptom reporting and current standards of care such as peak flow monitoring. A randomised controlled trial (RCT) is now underway.

Our aim is to license and share the platform with users, including hospitals, primary care networks and insurers, who can distribute it to their highest-risk asthma members – reducing costly hospitalisations and claim spend. With 3.3 million people living with asthma across Australia and New Zealand, and 32,000 avoidable hospital admissions each year in Australia alone, DIGIPREDICT aims to reduce costs and improve outcomes for asthma.

We are exhibiting on the New Zealand Pavilion and are actively seeking pilot partners, investors, and clinical collaborators.

Visit us at the New Zealand Pavilion · https://www.digipredict.io/ · hello@digipredict.io

website